IL-17A increases MHC class i expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis

Li Tao Han, Jia Qian Hu, Ben Ma, Duo Wen, Ting Ting Zhang, Zhong Wu Lu, Wen Jun Wei, Yu Long Wang, Yu Wang, Tian Liao, Qing Hai Ji

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The incidence of coexisting papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT) is increasing. The impact of HT on PTC prognosis and its possible mechanism remains controversial. Interleukin-17A (IL-17A) has been reported to participate in the pathogenesis of multiple autoimmune diseases and cancers. The aim of this study is to investigate the role of IL-17A in PTC with coexistent HT and evaluate the changes in tumor antigenicity. Methods: Expression of IL-17A and major histocompatibility complex (MHC) class I molecules were compared on PTC tissue samples with or without HT. PTC cell lines K1 and TPC-1 were stimulated with IL-17A and analyzed for MHC class I expression afterwards. Cluster of differentiation (CD) 8+T cell activation, production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-γ) as well as the programmed death-1 (PD-1) expression on lymphocytes were assessed by coculture of donor peripheral blood lymphocytes (PBLs) with IL-17A pretreated PTC cells. Results: Elevated IL-17A and MHC class I expression were observed in PTC tissue samples with coexistent HT. Stimulation of PTC cells with IL-17A effectively increased MHC class I expression in vitro. Coculture of PBLs with IL-17A pretreated PTC cells resulted in enhanced T cell activation (%CD25+ of CD3+T cells) and increased IL-2 production along with decreased IFN-γsecretion and PD-1 expression of the lymphocytes. Conclusions: Papillary thyroid cancer with coexisting Hashimoto's thyroiditis presents elevated MHC class I expression, which may be the result of IL-17A secretion. T cell activation is enhanced in vitro by IL-17A and may provide future utility in PTC immunotherapy.

Original languageEnglish (US)
Article number52
JournalDiagnostic pathology
Volume14
Issue number1
DOIs
StatePublished - Jun 4 2019

Fingerprint

Hashimoto Disease
Interleukin-17
Major Histocompatibility Complex
T-Lymphocytes
Lymphocytes
Coculture Techniques
Interferon-gamma
Interleukin-2
Papillary Thyroid cancer
Blood Donors
Immunotherapy
Autoimmune Diseases
Neoplasms

Keywords

  • Hashimoto's thyroiditis
  • Immune escape
  • Interleukin-17A
  • MHC class I molecule
  • PD-1/PD-L1
  • Papillary thyroid cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

IL-17A increases MHC class i expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis. / Han, Li Tao; Hu, Jia Qian; Ma, Ben; Wen, Duo; Zhang, Ting Ting; Lu, Zhong Wu; Wei, Wen Jun; Wang, Yu Long; Wang, Yu; Liao, Tian; Ji, Qing Hai.

In: Diagnostic pathology, Vol. 14, No. 1, 52, 04.06.2019.

Research output: Contribution to journalArticle

Han, Li Tao ; Hu, Jia Qian ; Ma, Ben ; Wen, Duo ; Zhang, Ting Ting ; Lu, Zhong Wu ; Wei, Wen Jun ; Wang, Yu Long ; Wang, Yu ; Liao, Tian ; Ji, Qing Hai. / IL-17A increases MHC class i expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis. In: Diagnostic pathology. 2019 ; Vol. 14, No. 1.
@article{d92ee4acad09459fbc1b47b40e108209,
title = "IL-17A increases MHC class i expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis",
abstract = "Background: The incidence of coexisting papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT) is increasing. The impact of HT on PTC prognosis and its possible mechanism remains controversial. Interleukin-17A (IL-17A) has been reported to participate in the pathogenesis of multiple autoimmune diseases and cancers. The aim of this study is to investigate the role of IL-17A in PTC with coexistent HT and evaluate the changes in tumor antigenicity. Methods: Expression of IL-17A and major histocompatibility complex (MHC) class I molecules were compared on PTC tissue samples with or without HT. PTC cell lines K1 and TPC-1 were stimulated with IL-17A and analyzed for MHC class I expression afterwards. Cluster of differentiation (CD) 8+T cell activation, production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-γ) as well as the programmed death-1 (PD-1) expression on lymphocytes were assessed by coculture of donor peripheral blood lymphocytes (PBLs) with IL-17A pretreated PTC cells. Results: Elevated IL-17A and MHC class I expression were observed in PTC tissue samples with coexistent HT. Stimulation of PTC cells with IL-17A effectively increased MHC class I expression in vitro. Coculture of PBLs with IL-17A pretreated PTC cells resulted in enhanced T cell activation ({\%}CD25+ of CD3+T cells) and increased IL-2 production along with decreased IFN-γsecretion and PD-1 expression of the lymphocytes. Conclusions: Papillary thyroid cancer with coexisting Hashimoto's thyroiditis presents elevated MHC class I expression, which may be the result of IL-17A secretion. T cell activation is enhanced in vitro by IL-17A and may provide future utility in PTC immunotherapy.",
keywords = "Hashimoto's thyroiditis, Immune escape, Interleukin-17A, MHC class I molecule, PD-1/PD-L1, Papillary thyroid cancer",
author = "Han, {Li Tao} and Hu, {Jia Qian} and Ben Ma and Duo Wen and Zhang, {Ting Ting} and Lu, {Zhong Wu} and Wei, {Wen Jun} and Wang, {Yu Long} and Yu Wang and Tian Liao and Ji, {Qing Hai}",
year = "2019",
month = "6",
day = "4",
doi = "10.1186/s13000-019-0832-2",
language = "English (US)",
volume = "14",
journal = "Diagnostic Pathology",
issn = "1746-1596",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - IL-17A increases MHC class i expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis

AU - Han, Li Tao

AU - Hu, Jia Qian

AU - Ma, Ben

AU - Wen, Duo

AU - Zhang, Ting Ting

AU - Lu, Zhong Wu

AU - Wei, Wen Jun

AU - Wang, Yu Long

AU - Wang, Yu

AU - Liao, Tian

AU - Ji, Qing Hai

PY - 2019/6/4

Y1 - 2019/6/4

N2 - Background: The incidence of coexisting papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT) is increasing. The impact of HT on PTC prognosis and its possible mechanism remains controversial. Interleukin-17A (IL-17A) has been reported to participate in the pathogenesis of multiple autoimmune diseases and cancers. The aim of this study is to investigate the role of IL-17A in PTC with coexistent HT and evaluate the changes in tumor antigenicity. Methods: Expression of IL-17A and major histocompatibility complex (MHC) class I molecules were compared on PTC tissue samples with or without HT. PTC cell lines K1 and TPC-1 were stimulated with IL-17A and analyzed for MHC class I expression afterwards. Cluster of differentiation (CD) 8+T cell activation, production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-γ) as well as the programmed death-1 (PD-1) expression on lymphocytes were assessed by coculture of donor peripheral blood lymphocytes (PBLs) with IL-17A pretreated PTC cells. Results: Elevated IL-17A and MHC class I expression were observed in PTC tissue samples with coexistent HT. Stimulation of PTC cells with IL-17A effectively increased MHC class I expression in vitro. Coculture of PBLs with IL-17A pretreated PTC cells resulted in enhanced T cell activation (%CD25+ of CD3+T cells) and increased IL-2 production along with decreased IFN-γsecretion and PD-1 expression of the lymphocytes. Conclusions: Papillary thyroid cancer with coexisting Hashimoto's thyroiditis presents elevated MHC class I expression, which may be the result of IL-17A secretion. T cell activation is enhanced in vitro by IL-17A and may provide future utility in PTC immunotherapy.

AB - Background: The incidence of coexisting papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT) is increasing. The impact of HT on PTC prognosis and its possible mechanism remains controversial. Interleukin-17A (IL-17A) has been reported to participate in the pathogenesis of multiple autoimmune diseases and cancers. The aim of this study is to investigate the role of IL-17A in PTC with coexistent HT and evaluate the changes in tumor antigenicity. Methods: Expression of IL-17A and major histocompatibility complex (MHC) class I molecules were compared on PTC tissue samples with or without HT. PTC cell lines K1 and TPC-1 were stimulated with IL-17A and analyzed for MHC class I expression afterwards. Cluster of differentiation (CD) 8+T cell activation, production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-γ) as well as the programmed death-1 (PD-1) expression on lymphocytes were assessed by coculture of donor peripheral blood lymphocytes (PBLs) with IL-17A pretreated PTC cells. Results: Elevated IL-17A and MHC class I expression were observed in PTC tissue samples with coexistent HT. Stimulation of PTC cells with IL-17A effectively increased MHC class I expression in vitro. Coculture of PBLs with IL-17A pretreated PTC cells resulted in enhanced T cell activation (%CD25+ of CD3+T cells) and increased IL-2 production along with decreased IFN-γsecretion and PD-1 expression of the lymphocytes. Conclusions: Papillary thyroid cancer with coexisting Hashimoto's thyroiditis presents elevated MHC class I expression, which may be the result of IL-17A secretion. T cell activation is enhanced in vitro by IL-17A and may provide future utility in PTC immunotherapy.

KW - Hashimoto's thyroiditis

KW - Immune escape

KW - Interleukin-17A

KW - MHC class I molecule

KW - PD-1/PD-L1

KW - Papillary thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=85066817516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066817516&partnerID=8YFLogxK

U2 - 10.1186/s13000-019-0832-2

DO - 10.1186/s13000-019-0832-2

M3 - Article

C2 - 31159823

AN - SCOPUS:85066817516

VL - 14

JO - Diagnostic Pathology

JF - Diagnostic Pathology

SN - 1746-1596

IS - 1

M1 - 52

ER -